SABS
SAB Biotherapeutics Inc
2.90$
+0.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +196.2% | -15.0% | -13.3% | -13.1% | -17.8% | -13.7% | -21.0% | +508.9% | -5.8% | +43.8% | -4.1% | |
| – | +1,783.4% | -20.3% | -15.7% | -17.8% | -26.9% | -31.5% | -42.9% | +1,117.0% | -10.8% | +11.6% | -4.3% | |
| – | +2,232.2% | -75.2% | +22.9% | -46.8% | -3.0% | -36.6% | -34.5% | +696.9% | -64.3% | +95.4% | -59.7% | |
| – | +2,232.2% | -22.1% | -15.3% | -18.6% | -31.7% | -38.1% | -55.5% | +1,840.7% | -12.9% | +11.2% | -4.4% | |
| – | – | – | +16.4% | -56.9% | -43.4% | -61.1% | – | – | +69.1% | +64.2% | +18.6% | |
| – | +103.7% | -30.4% | -15.0% | +7.1% | +7.9% | -8.3% | +8.4% | +1.4% | +16.0% | -0.4% | +10.4% | |
| – | +17.4% | -23.2% | -9.1% | +16.7% | -9.5% | +21.0% | +10.6% | +1.1% | -1.0% | -7.8% | +18.8% | |
| – | +54.4% | -18.3% | -19.9% | -56.7% | +54.7% | +32.7% | -10.6% | +2.6% | -3.7% | -3.2% | -30.4% | |
| – | -12.7% | +31.1% | -5.5% | +10.7% | +30.7% | +48.7% | +4.0% | +12.7% | +6.5% | +12.7% | +8.7% | |
| – | +275.6% | -7.8% | -12.7% | -20.0% | -29.6% | -17.6% | -43.9% | +1,273.8% | -8.2% | +50.0% | -5.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +13.1% | +55.9% | +0.1% | +0.0% | +0.0% | +0.3% | +0.0% | +737.7% | -38.9% | +12.5% | +48.9% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.